DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

DexCom, Inc. (NASDAQ:DXCM) has received a consensus rating of “Moderate Buy” from the twenty-seven analysts that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, nineteen have issued a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $86.3043.

A number of equities research analysts have issued reports on the stock. Robert W. Baird set a $82.00 price objective on shares of DexCom in a research report on Friday, October 31st. The Goldman Sachs Group cut their price objective on DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. Royal Bank Of Canada decreased their target price on DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a research report on Friday, October 31st. Citigroup reissued a “buy” rating and issued a $77.00 price target (up from $75.00) on shares of DexCom in a report on Thursday, December 11th. Finally, UBS Group decreased their price objective on shares of DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a report on Monday, November 3rd.

DexCom Stock Up 0.4%

DXCM stock opened at $69.54 on Friday. The firm has a market capitalization of $27.12 billion, a PE ratio of 38.63, a P/E/G ratio of 1.25 and a beta of 1.48. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45. DexCom has a twelve month low of $54.11 and a twelve month high of $93.25. The stock’s 50 day moving average is $65.03 and its 200-day moving average is $71.55.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. The business had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. DexCom had a return on equity of 30.65% and a net margin of 15.96%.DexCom’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.45 EPS. Sell-side analysts expect that DexCom will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In other news, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the transaction, the director owned 27,031 shares of the company’s stock, valued at $1,569,690.17. This represents a 3.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jacob Steven Leach acquired 18,200 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was purchased at an average cost of $55.04 per share, with a total value of $1,001,728.00. Following the acquisition, the chief operating officer owned 331,697 shares in the company, valued at $18,256,602.88. The trade was a 5.81% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold a total of 7,866 shares of company stock worth $448,177 in the last quarter. Insiders own 0.32% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Andra AP fonden purchased a new stake in shares of DexCom during the 2nd quarter valued at $26,000. Twin Peaks Wealth Advisors LLC purchased a new stake in DexCom during the second quarter valued at about $26,000. SJS Investment Consulting Inc. lifted its stake in DexCom by 4,800.0% during the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after purchasing an additional 384 shares during the last quarter. Financial Consulate Inc. bought a new stake in DexCom during the third quarter worth about $29,000. Finally, CVA Family Office LLC boosted its holdings in shares of DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.